Intra-procedural anticoagulation and post-procedural hemoglobin fall in atrial fibrillation ablation with minimally interrupted direct oral anticoagulants: comparisons across 4 drugs

Purpose Thromboembolic or hemorrhagic complications related to atrial fibrillation (AF) ablation are rare, and thus, it is difficult to compare their frequency across different direct oral anticoagulants (DOACs). We aimed to compare the intra-ablation blood coagulability and post-procedural hemoglob...

Full description

Saved in:
Bibliographic Details
Published in:Journal of interventional cardiac electrophysiology 2021-09, Vol.61 (3), p.551-557
Main Authors: Sairaku, Akinori, Morishima, Nobuyuki, Matsumura, Hiroya, Amioka, Michitaka, Maeda, Junji, Watanabe, Yoshikazu, Nakano, Yukiko
Format: Article
Language:English
Subjects:
Ablation
Anticoagulants
Blood
Cardiac arrhythmia
Cardiology
Clotting
Complications
Fibrillation
Hemoglobin
Hemorrhage
Heparin
Medicine
Medicine & Public Health
Thromboembolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Thromboembolic or hemorrhagic complications related to atrial fibrillation (AF) ablation are rare, and thus, it is difficult to compare their frequency across different direct oral anticoagulants (DOACs). We aimed to compare the intra-ablation blood coagulability and post-procedural hemoglobin fall as alternatives to those complications across 4 DOACs. Methods We enrolled AF patients younger than 65 years old in 3 cardiovascular centers who skipped a single dose of apixaban, dabigatran, edoxaban, and rivaroxaban, prior to the ablation. Endpoints included the activated clotting time (ACT), heparin requirement during the ablation, and drop in the hemoglobin level 24 h after the procedure. Results The time-course curves of the ACT differed significantly across the patients with apixaban ( N  = 113), dabigatran ( N  = 130), edoxaban ( N  = 144), and rivaroxaban ( N  = 81), with its highest level in the dabigatran group ( P  
ISSN:1383-875X
1572-8595
DOI:10.1007/s10840-020-00851-6